Anirudh Saraswathula1, Michelle M Chen2, Seshadri C Mudumbai3,4, Alice S Whittemore5, Vasu Divi2. 1. 1 Stanford University School of Medicine, Stanford, California, USA. 2. 2 Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, USA. 3. 3 Anesthesiology and Perioperative Care Service, VA Palo Alto Health Care System, Palo Alto, California, USA. 4. 4 Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University School of Medicine, Stanford, California, USA. 5. 5 Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California, USA.
Abstract
OBJECTIVES: Despite the epidemic of opioid overuse among American patients, there are limited data regarding the prevalence of such use among patients with head and neck cancer (HNC). Here, we report on the prevalence of persistent postoperative opioid (PPO) use and its risk factors among older patients with HNC undergoing surgery. STUDY DESIGN: Retrospective cohort study. SETTING: Surveillance, Epidemiology, and End Results (SEER)-Medicare linked cancer registry-claims database. SUBJECTS AND METHODS: We identified patients aged 66 years or older who were diagnosed with HNC from 2008 to 2013, underwent primary surgical resection for their cancers, and met certain insurance and discharge criteria. The primary outcome was PPO use, defined as new opioid prescriptions 90 to 180 days postoperatively. We used multivariable logistic regression to evaluate associations between PPO use and factors such as demographics and postoperative treatment. RESULTS: Of the 1190 eligible patients with HNC, 866 (72.8%) received opioid prescriptions attributable to their surgery. Among these 866 patients, the prevalence of PPO use was 33.3% overall; it was 48.3% among the 428 patients with preoperative opioid use compared to 18.5% among the 438 opioid-naive patients (adjusted odds ratio [OR], 3.96; 95% confidence interval [CI], 2.80-5.59). Other factors associated with PPO use include postoperative radiotherapy (OR, 1.99; 95%, CI 1.33-2.98) and Charlson comorbidity index (OR, 1.20; 95% CI, 1.03-1.41). Postoperative chemotherapy (OR, 1.19; 95% CI, 0.73-1.95) was not significantly associated with PPO use. CONCLUSIONS: PPO use is a substantial problem in older surgical patients with HNC, one that warrants consideration of alternative treatment strategies and continued examination of prescription guidelines for patients with HNC.
OBJECTIVES: Despite the epidemic of opioid overuse among American patients, there are limited data regarding the prevalence of such use among patients with head and neck cancer (HNC). Here, we report on the prevalence of persistent postoperative opioid (PPO) use and its risk factors among older patients with HNC undergoing surgery. STUDY DESIGN: Retrospective cohort study. SETTING: Surveillance, Epidemiology, and End Results (SEER)-Medicare linked cancer registry-claims database. SUBJECTS AND METHODS: We identified patients aged 66 years or older who were diagnosed with HNC from 2008 to 2013, underwent primary surgical resection for their cancers, and met certain insurance and discharge criteria. The primary outcome was PPO use, defined as new opioid prescriptions 90 to 180 days postoperatively. We used multivariable logistic regression to evaluate associations between PPO use and factors such as demographics and postoperative treatment. RESULTS: Of the 1190 eligible patients with HNC, 866 (72.8%) received opioid prescriptions attributable to their surgery. Among these 866 patients, the prevalence of PPO use was 33.3% overall; it was 48.3% among the 428 patients with preoperative opioid use compared to 18.5% among the 438 opioid-naive patients (adjusted odds ratio [OR], 3.96; 95% confidence interval [CI], 2.80-5.59). Other factors associated with PPO use include postoperative radiotherapy (OR, 1.99; 95%, CI 1.33-2.98) and Charlson comorbidity index (OR, 1.20; 95% CI, 1.03-1.41). Postoperative chemotherapy (OR, 1.19; 95% CI, 0.73-1.95) was not significantly associated with PPO use. CONCLUSIONS: PPO use is a substantial problem in older surgical patients with HNC, one that warrants consideration of alternative treatment strategies and continued examination of prescription guidelines for patients with HNC.
Entities:
Keywords:
claims data; head and neck cancer; opioids
Authors: Jennifer P March; James Y Lim; Katherine L Manzione; Michelle Buncke; Maisie L Shindo Journal: JAMA Otolaryngol Head Neck Surg Date: 2022-06-01 Impact factor: 8.961
Authors: Lucas K Vitzthum; Paul Riviere; Paige Sheridan; Vinit Nalawade; Rishi Deka; Timothy Furnish; Loren K Mell; Brent Rose; Mark Wallace; James D Murphy Journal: J Natl Cancer Inst Date: 2020-07-01 Impact factor: 13.506
Authors: Lu Chen; Jessica Chubak; Onchee Yu; Gaia Pocobelli; Rebecca A Ziebell; Erin J Aiello Bowles; Monica M Fujii; Andrew T Sterrett; Jennifer M Boggs; Andrea N Burnett-Hartman; Debra P Ritzwoller; Rebecca A Hubbard; Denise M Boudreau Journal: Cancer Causes Control Date: 2019-10-30 Impact factor: 2.506
Authors: Michael Eggerstedt; Kerstin M Stenson; Emily A Ramirez; Hannah N Kuhar; Danny B Jandali; Deborah Vaughan; Samer Al-Khudari; Ryan M Smith; Peter C Revenaugh Journal: JAMA Facial Plast Surg Date: 2019-09-01 Impact factor: 4.611
Authors: Danielle R Trakimas; Carlos Perez-Heydrich; Rajarsi Mandal; Marietta Tan; Christine G Gourin; Carole Fakhry; Wayne M Koch; Jonathon O Russell; Ralph P Tufano; David W Eisele; Peter S Vosler Journal: Front Psychiatry Date: 2022-07-08 Impact factor: 5.435
Authors: Mary Falcone; Chongliang Luo; Justin E Bekelman; Caryn Lerman; Yong Chen; David Birtwell; Martin Cheatle; Rui Duan; Peter E Gabriel; Lifang He; Emily M Ko; Heinz-Josef Lenz; Nebojsa Mirkovic; Danielle L Mowery; E Andrew Ochroch; E Carter Paulson; Emily Schriver; Robert A Schnoll Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-08-28 Impact factor: 4.254